NovoCure (STU:038) Net Issuance of Preferred Stock : €0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is NovoCure Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

NovoCure's net issuance of preferred for the three months ended in Mar. 2024 was €0.0 Mil. The number is 0, which means that NovoCure has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

NovoCure's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2024 was €0.0 Mil.

NovoCure Net Issuance of Preferred Stock Historical Data

The historical data trend for NovoCure's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Net Issuance of Preferred Stock Chart

NovoCure Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

NovoCure Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

NovoCure Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

NovoCure Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of NovoCure's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure (STU:038) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (STU:038) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

NVCR:USA

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.

NovoCure (STU:038) Headlines

No Headlines